<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805283</url>
  </required_header>
  <id_info>
    <org_study_id>D1690R00026</org_study_id>
    <nct_id>NCT02805283</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Patient Satisfaction Survey</brief_title>
  <official_title>Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optum, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the diabetes related treatment satisfaction for
      patients with type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-sectional, observational patient survey study. Study subjects will be adult
      commercial members of the large US health plan affiliated with Optum with evidence of T2D
      initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey
      mailing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2016</start_date>
  <completion_date type="Actual">October 29, 2018</completion_date>
  <primary_completion_date type="Actual">October 29, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Condition-specific treatment satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Condition-specific treatment satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study (MOS) Short Form Health Survey SF-12 or SF-36</measure>
    <time_frame>4 weeks</time_frame>
    <description>MOS Short Form Health Survey SF-12 or SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morisky Medication Adherence Scale</measure>
    <time_frame>1 month</time_frame>
    <description>Medication adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Fear Survey</measure>
    <time_frame>4 weeks</time_frame>
    <description>Fear of hypoglycemia (HFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported body weight</measure>
    <time_frame>1 month</time_frame>
    <description>Self-reported body weight</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">653</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin, dapagliflozin/met ER</arm_group_label>
    <description>Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
    <description>Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 Diabetes patients with administrative claims data from Optum Research Database (US
        Commercial Claims Data)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the
             most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication
             during the 6 months prior to sample identification.

          -  Evidence of T2D diagnosis.

          -  Age â‰¥18 as of the drug index date.

          -  6 months of continuous enrollment in a commercial health plan with both pharmacy and
             medical benefits during the identification period through the patient interview sample
             identification date.

          -  Self-reported T2D diagnosis during the patient interview.

        Exclusion Criteria:

          -  Patients with evidence of type 1 diabetes mellitus and unknown type

          -  Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Bell, PharmD, MSPhr</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reasearch Site</name>
      <address>
        <city>Eden Prairie</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D1690R00026&amp;amp;attachmentIdentifier=c9c5429d-e8a7-4a55-a360-562446e71816&amp;amp;fileName=CSR_Synopsis_D1690R00026.pdf&amp;amp;versionIdentifier=</url>
    <description>CSR synopsis</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

